Down-regulated E-cadherin expression is associated with poor five-year overall survival in bone and soft tissue sarcoma: Results of a meta-analysis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Wang, Ning ^a   He, Yong Lai ^a   Pang, Li Juan ^a   Zou, Hong ^a   Liu, Chun Xia ^a   Zhao, Jin ^a   Hu, Jian Ming ^a   Zhang, Wen Jie ^a   Qi, Yan ^a   Li, Feng ^a  

^a SHIHEZI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

UVOMORULIN; CADHERIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOWN REGULATION; EWING SARCOMA; HUMAN; LEIOMYOSARCOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SEX DIFFERENCE; SOFT TISSUE SARCOMA; SURVIVAL RATE; SYNOVIAL SARCOMA; SYSTEMATIC REVIEW; TUMOR VOLUME; BONE TUMOR; FEMALE; GENETICS; MALE; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SARCOMA; SOFT TISSUE TUMOR; SURVIVAL ANALYSIS;

BONE NEOPLASMS; CADHERINS; DOWN-REGULATION; FEMALE; HUMANS; MALE; PROGNOSIS; SARCOMA; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84926379392     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121448     Document Type: Article

References (38)

1. Skubitz KM, D'Adamo DR. Sarcoma. Mayo Clin Proc. 2007; 82: 1409-1432. PMID: 17976362
2. Presant CA, Russell WO, Alexander RW, Fu YS. Soft-tissue and bone sarcoma histopathologypeer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience. J Clin Oncol. 1986; 4: 1658-1661. PMID: 3772418
3. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M, et al. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011; 11: 541-557. doi: 10.1038/nrc3087 PMID: 21753790
4. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009; 1: a003129. doi: 10.1101/cshperspect.a003129 PMID: 20457567
5. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19: 156-172. doi: 10.1038/cr.2009.5 PMID: 19153598
6. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-1428. doi: 10.1172/JCI39104 PMID: 19487818
7. Kang H, Min BS, Lee KY, Kim NK, Kim SN, Choi J, et al. Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol. 2011; 18: 711-719. doi: 10.1245/s10434-010-1338-z PMID: 20865330
8. Sekar P, Bharti JN, Nigam JS, Sharma A, Soni PB. Evaluation of p53, HoxD10, and E-Cadherin Status in Breast Cancer and Correlation with Histological Grade and Other Prognostic Factors. J Oncol. 2014; 2014: 702527. doi: 10.1155/2014/702527 PMID: 24634677
9. Dian D, Bruning A, Mylonas I. E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis. Arch Gynecol Obstet. 2011; 284: 437-443. doi: 10.1007/s00404-010-1657-0 PMID: 20803206
10. Gogou PN, Batistatou A, Pakos EE, Apostolikas N, Stefanou D, Tsekeris PG, et al. Expression of Ecadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas. Clin Transl Oncol. 2009; 11: 548-551. PMID: 19661031
11. Yoo J, Park S, Kang CS, Kang SJ, Kim BK. Expression of E-cadherin and p53 proteins in human soft tissue sarcomas. Arch Pathol Lab Med. 2002; 126: 33-38. PMID: 11800644
12. Saito T, Oda Y, Sugimachi K, Kawaguchi K, Tamiya S, Tanaka K, et al. E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features. Am J Pathol. 2001; 159: 2117-2124. PMID: 11733362
13. Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Kawai A, Sonobe H, et al. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression. Am J Surg Pathol. 2007; 31: 85-94. PMID: 17197923
14. Yang J, Eddy JA, Pan Y, Hategan A, Tabus I, Wang Y, et al. Integrated proteomics and genomics analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug. Mol Cell Proteomics. 2010; 9: 2405-2413. doi: 10.1074/mcp.M110.000240 PMID: 20651304
15. Yin K, Liao Q, He H, Zhong D. Prognostic value of Twist and E-cadherin in patients with osteosarcoma. Med Oncol. 2012; 29: 3449-3455. doi: 10.1007/s12032-012-0317-6 PMID: 22847601
16. Machado I, Lopez-Guerrero JA, Navarro S, Alberghini M, Scotlandi K, Picci P, et al. Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance? Virchows Arch. 2012; 461: 333-337. doi: 10.1007/s00428-012-1288-x PMID: 22898789
17. Tian W, Wang G, Yang J, Pan Y, Ma Y. Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas. Med Oncol. 2013; 30: 401. doi: 10.1007/s12032-012-0401-y PMID: 23292832
18. Qi Y, Wang CC, He YL, Zou H, Liu CX, Pang LJ, et al. The correlation between morphology and the expression of TGF-beta signaling pathway proteins and epithelial-mesenchymal transition-related proteins in synovial sarcomas. Int J Clin Exp Pathol. 2013; 6: 2787-2799. PMID: 24294365
19. Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol. 2000; 192: 342-350. PMID: 11054718
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101. PMID: 7786990
21. Irwig L, Macaskill P, Berry G, Glasziou P. Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ. 1998; 316: 470; author reply 470-471. PMID: 9492688
22. Koo JS, Jung W, Jeong J. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer. Jpn J Clin Oncol. 2009; 39: 560-568. doi: 10.1093/jjco/hyp065 PMID: 19531543
23. Ansenberger K, Zhuge Y, Lagman JA, Richards C, Barua A, Bahr JM, et al. E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer. Gynecol Oncol. 2009; 113: 362-369. doi: 10.1016/j.ygyno.2009.02.011 PMID: 19321195
24. Huiping C, Kristjansdottir S, Jonasson JG, Magnusson J, Egilsson V, Ingvarsson S, et al. Alterations of E-cadherin and beta-catenin in gastric cancer. BMC Cancer. 2001; 1: 16. PMID: 11747475
25. Sampson VB, David JM, Puig I, Patil PU, de Herreros AG, Thomas GV, et al. Wilms' tumor protein induces an epithelial-mesenchymal hybrid differentiation state in clear cell renal cell carcinoma. PLoS One. 2014; 9: e102041. doi: 10.1371/journal.pone.0102041 PMID: 25025131
26. Wang SC, Lin XL, Li J, Zhang TT, Wang HY, Shi JW, et al. MicroRNA-122 Triggers Mesenchymal-Epithelial Transition and Suppresses Hepatocellular Carcinoma Cell Motility and Invasion by Targeting RhoA. PLoS One. 2014; 9: e101330. doi: 10.1371/journal.pone.0101330 PMID: 24992599
27. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139: 871-890. doi: 10.1016/j.cell.2009.11.007 PMID: 19945376
28. Luo SL, Xie YG, Li Z,Ma JH, Xu X. E-cadherin expression and prognosis of oral cancer: a meta-analysis. Tumour Biol. 2014; 35(6): 5533-7. doi: 10.1007/s13277-014-1728-0 PMID: 24573611
29. He X, Chen Z, Jia M, Zhao X. Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One. 2013; 8: e70858. doi: 10.1371/journal.pone.0070858 PMID: 23923027
30. Peng HL, He L, Zhao X. Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis-results of a meta-analysis. Asian Pac J Cancer Prev. 2012; 13: 2003-2007. PMID: 22901162
31. Wisanuyotin T, Radapat K, Sirichativapee W, Paholpak P, Kosuwon W, Sumnanoont C, et al. Prognostic factors and clinical outcomes in synovial sarcoma of the extremities. Asia Pac J Clin Oncol. 2013; 9: 80-85. doi: 10.1111/j.1743-7563.2012.01563.x PMID: 22898085
32. Sato H, Hasegawa T, Abe Y, Sakai H, Hirohashi S. Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation. Hum Pathol. 1999; 30: 1344-1349. PMID: 10571515
33. Wardelmann E, Schildhaus HU, Merkelbach-Bruse S, Hartmann W, Reichardt P, Hohenberger P, et al. Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies. Ann Oncol 21 Suppl. 2010; 7: vii265-269.
34. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 21 Suppl. 2010; 7: vii320-325.
35. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010; 11: 184-192. doi: 10.1016/S1470-2045(09)70286-4 PMID: 20152770
36. Gogou P, Pakos E, Batistatou A, Panelos I, Briasoulis E, Stefanou D, et al. Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases. World J Surg Oncol. 2012; 10: 28. doi: 10.1186/1477-7819-10-28 PMID: 22300273
37. Smith ME, Brown JI, Fisher C. Epithelioid sarcoma: presence of vascular-endothelial cadherin and lack of epithelial cadherin. Histopathology. 1998; 33: 425-431. PMID: 9839166
38. Saito T, Oda Y, Itakura E, Shiratsuchi H, Kinoshita Y, Oshiro Y, et al. Expression of intercellular adhesion molecules in epithelioid sarcoma and malignant rhabdoid tumor. Pathol Int. 2001; 51: 532-542. PMID: 11472566